Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase SHPRH (SHPRH) is a multifunctional protein characterized by DNA helicase, PHD, and RING finger domains, and is ubiquitously expressed in human tissues[2][3][4]. It acts predominantly as a nucleosome-stimulated ATPase and E3 ubiquitin ligase, orchestrating DNA repair by promoting non-canonical polyubiquitination of PCNA in response to genotoxic stress[2][7]. SHPRH is a functional homolog of yeast RAD5 and is implicated in chromatin remodeling and transcriptional regulation through its domain architecture[2][3][5]. Dysregulation and reduced expression of SHPRH have been observed in cancers such as glioblastoma, where it acts as a tumor suppressor by stabilizing its own protein levels and regulating cell proliferation via ubiquitination pathways[1][2]. SHPRH gene variations are associated with inherited DNA repair syndromes including xeroderma pigmentosum and Fanconi anemia[2][5].
Drugs targeting this protein would theoretically modulate DNA repair via influencing ubiquitination of PCNA and related DNA damage response; currently, no specific drugs are listed in search results[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase SHPRH (SHPRH).